hENT1 RNA and Protein in Combination May Act as Predictive Biomarkers for Survival for Patients Treated With Adjuvant Gemcitabine in Pancreatic Cancer

被引：0

作者：

Hale, J. ^{[1
]}

Evans, A. ^{[1
]}

Aughton, K. ^{[1
]}

Elander, N. O. ^{[1
,2
]}

Ghaneh, P. ^{[1
]}

Neoptolemos, J. P. ^{[3
]}

Jackson, R. ^{[1
]}

Cox, T. F. ^{[1
]}

Campbell, F. ^{[1
]}

Halloran, C. M. ^{[1
]}

Mackey, J. R. ^{[4
,5
]}

Scarfe, A. G. ^{[4
,5
]}

Valle, J. W. ^{[6
]}

Carter, R. ^{[7
]}

Cunningham, D. ^{[8
,9
]}

Tebbutt, N. C. ^{[10
]}

Goldstein, D. ^{[11
,12
]}

Shannon, J. ^{[13
,14
]}

Glimelius, B. ^{[15
]}

Deakin, M. ^{[16
]}

Charnley, R. M. ^{[17
]}

Anthoney, A. ^{[18
]}

Lerch, M. M. ^{[19
]}

Mayerle, J. ^{[19
,20
]}

Costello, E. ^{[1
]}

Palmer, D. H. ^{[1
]}

Buechler, M. W. ^{[3
]}

Greenhalf, W. ^{[1
]}

机构：

[1] Univ Liverpool, Liverpool Canc Trials Unit, Liverpool, Merseyside, England

[2] Linkoping Univ, Dept Oncol, Linkoping, Sweden

[3] Heidelberg Univ, Dept Surg, Heidelberg, Germany

[4] Cross Canc Inst, Edmonton, AB, Canada

[5] Univ Alberta, Edmonton, AB, Canada

[6] Univ Manchester, Christie NHS Fdn Trust, Manchester, Lancs, England

[7] Glasgow Royal Infirm, Glasgow, Lanark, Scotland

[8] Royal Marsden Natl Hlth Serv NHS Fdn Trust, London, England

[9] Royal Marsden Natl Hlth Serv NHS Fdn Trust, Surrey, England

[10] Austin Hlth, Melbourne, Vic, Australia

[11] Univ New South Wales, Prince Wales Hosp, Sydney, NSW, Australia

[12] Univ New South Wales, Sch Clin, Sydney, NSW, Australia

[13] Nepean Canc Ctr, Kingswood, NSW, Australia

[14] Univ Sydney, Sydney, NSW, Australia

[15] Uppsala Univ, Dept Immunol Genet & Pathol, Uppsala, Sweden

[16] North Staffs Univ Hosp, Stoke On Trent, Staffs, England

[17] Freeman Rd Hosp, Newcastle Upon Tyne, Tyne & Wear, England

[18] St James Univ Hosp, Leeds, W Yorkshire, England

[19] Univ Med Greifswald, Dept Med A, Greifswald, Germany

[20] Klinikum LMU Munchen Grosshadern, Med Klin & Poliklin 2, Munich, Germany

来源：

PANCREAS | 2019年 / 48卷 / 10期

关键词：

D O I：

暂无

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

引用

页码：1436 / 1437

页数：2

共 50 条

[31] Putative Predictive Biomarkers of Survival in Patients with Metastatic Pancreatic Adenocarcinoma Treated with Gemcitabine and Ganitumab, an IGF1R Inhibitor
McCaffery, Ian
Tudor, Yanyan
Deng, Hongjie
Tang, Rui
Suzuki, Samuel
Badola, Sunita
Kindler, Hedy L.
Fuchs, Charles S.
Loh, Elwyn
Patterson, Scott D.
Chen, Li
Gansert, Jennifer L.
CLINICAL CANCER RESEARCH, 2013, 19 (15) : 4282 - 4289
[32] Cytidine Deaminase (CDA) Transcript Analysis Complements hENT1 Protein Staining in Predicting Gemcitabine Response in the ESPAC-3 Pancreatic Cancer Cohort
Elander, N.
Aughton, K.
Ghaneh, P.
Neoptolemos, J. P.
Costello, E.
Palmer, D.
Cox, T.
Campbell, F.
Garner, E.
Evans, A. S.
Rimmer, N.
Halloran, C.
Buechler, M. W.
Greenhalf, W.
PANCREAS, 2015, 44 (08) : 1371 - 1371
[33] Human equilibrative nucleoside transporter 1 (hENT1) protein is associated with short survival in resected ampullary cancer
Santini, D.
Perrone, G.
Vincenzi, B.
Lai, R.
Cass, C.
Alloni, R.
Rabitti, C.
Antinori, A.
Vecchio, F.
Morini, S.
Magistrelli, P.
Coppola, R.
Mackey, J. R.
Tonini, G.
ANNALS OF ONCOLOGY, 2008, 19 (04) : 724 - 728
[34] The expression of human equilibrative nucleoside transporter 1 (hENT1) is associated with overall survival in advanced biliary tract carcinoma (BTC) treated with gemcitabine
Murata, Akihiro
Amano, Ryousuke
Kimura, Kenjiro
Yamada, Nobuya
Nakata, Bunzo
Nagahara, Hisashi
Noda, Eiji
Kubo, Naoshi
Tanaka, Hiroaki
Muguruma, Kazuya
Yashiro, Masakazu
Maeda, Kiyoshi
Ohira, Masaichi
Ishikawa, Tetsurou
Hirakawa, Kosei
CANCER RESEARCH, 2012, 72
[35] hENT-1 Expression in Circulating Tumor Cells is a Potential Predictive Biomarker of Gemcitabine Outcome in Pancreatic Cancer Patients
Ma, Y. S.
Zhao, X. D.
Tian, X. D.
Yang, Y. M.
PANCREAS, 2019, 48 (10) : 1483 - 1484
[36] Adenoviral-mediated overexpression of human equilibrative nucleoside transporter 1 (hENT1) enhances gemcitabine response in human pancreatic cancer
Perez-Torras, Sandra
Garcia-Manteiga, Jose
Mercade, Elena
Casado, F. Javier
Carbo, Neus
Pastor-Anglada, Marcal
Mazo, Adela
BIOCHEMICAL PHARMACOLOGY, 2008, 76 (03) : 322 - 329
[37] Human Equilibrative Nucleoside Transporter 1 (hENT1) Predicts the Asian Patient Response to Gemcitabine-Based Chemotherapy in Pancreatic Cancer
Xiao, Jian-Chun
Zhang, Tai-Ping
Zhao, Yu-Pei
HEPATO-GASTROENTEROLOGY, 2013, 60 (122) : 258 - 262
[38] Prognostic Role of hENT1 and RRM1 in Patients with Advanced Pleural Mesothelioma Treated with Second Line Gemcitabine Based Regimens
Cardona, Andres
Arrieta, Oscar
Rojas, Leonardo
Corrales, Luis
Wills, Beatriz
Oblitas, George
Bacon, Ludwing
Martin, Claudio
Cuello, Mauricio
Mas, Luis
Vargas, Carlos
Carranza, Hernan
Otero, Jorge
Perez, Maria
Gonzalez, Lisde
Chirinos, Luis
Rosell, Rafael
JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1366 - S1367
[39] Human equilibrative nucleoside transporter 1 (hENT1): Do we really have a new predictive biomarker of chemotherapy outcome in pancreatic cancer patients?
Mohelnikova-Duchonova, Beatrice
Melichar, Bohuslav
PANCREATOLOGY, 2013, 13 (06) : 558 - 563
[40] The high stromal SPARC expression is independently associated with poor survival of patients with resected pancreatic ductal adenocarcinoma treated with adjuvant gemcitabine in combination with S-1 or adjuvant gemcitabine alone
Shintakuya, Ryuta
Kondo, Naru
Murakami, Yoshiaki
Uemura, Kenichiro
Nakagawa, Naoya
Okano, Keisuke
Takahashi, Shinya
Sueda, Taijiro
PANCREATOLOGY, 2018, 18 (02) : 191 - 197

← 1 2 3 4 5 →